跳转至内容
Merck
CN

345M-1

Uroplakin III (AU-1) Mouse Monoclonal Antibody

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
AU-1, monoclonal
Application:
IHC (p)
Citations:
6
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

AU-1, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (345M-14), vial of 0.5 mL concentrate (345M-15), bottle of 1.0 mL predilute (345M-17), vial of 1.0 mL concentrate (345M-16), bottle of 7.0 mL predilute (345M-18)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

isotype

IgG1

control

bladder

shipped in

wet ice

storage temp.

2-8°C

visualization

membranous

Gene Information

human ... UPK3A(7380)

General description

Uroplakins (UPs) are a family of transmembrane proteins (UPs Ia, Ib, II and III) that are specific differentiation products of urothelial cells. In non-neoplastic mammalian urothelium, UPs are expressed in the luminal surface plasmalemma of superficial (umbrella) cells, forming complexes of 16-nm crystalline particles. Moll et al. reported that UPIII was detectable immunohistochemically in 29 of 55 primary (53%) and 23 of 35 metastatic (66%) urothelial carcinomas, whereas many non-urothelial carcinomas were UPIII-negative. The authors concluded that UPIII should be a valuable marker, especially for the specific identification of urothelial carcinomas in patients with metastases of unknown primary site. Recently, Olsburgh et al. studied UP gene expression in normal urothelium and bladder cancer specimens, and found that expression was absent after malignant transformation. Thus, UP expression might reflect the malignant potential of urothelial cancer cells as well as being cytodifferential markers of urothelial cells. Ohtsuka et al. concluded in their studies that UPIII expression was strongly associated with lower tumor grades, that lack of UPIII expression in urothelial tumors of the upper urinary tract was associated with much higher rates of metastases, and that 5-year specific survival was much worse for UPIII negative tumors (54%) than for UPIII positive tumors (100%). Apparently UPIII expression is a better indicator of the malignant potential of the tumour than the grade of the tumour.

Associated products: Thrombomodulin, CK7, CK20

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Analysis Note


IVD

IVD

IVD

RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Uroplakin III Positive Control Slides, Product No. 345S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


存储类别

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



R A Badalament et al.
The Journal of urology, 144(4), 859-863 (1990-10-01)
A total of 50 patients with primary transitional cell carcinoma of the upper urinary tract underwent deoxyribonucleic acid ploidy characterization by flow cytometric analysis of paraffin embedded specimens. The primary tumor was diploid in 29 patients (58%) and aneuploid in
M C Hall et al.
Urology, 52(4), 594-601 (1998-10-08)
To review a large single-center experience of patients treated for upper tract transitional cell carcinoma (TCC) with extended follow-up in order to identify patterns of recurrence, assess patient outcomes, and determine the impact of traditional prognostic factors. We reviewed 252
Sanjay Logani et al.
The American journal of surgical pathology, 27(11), 1434-1441 (2003-10-25)
Ovarian tumors containing cells with transitional cell morphology are recognized in the 1999 World Health Organization classification of ovarian tumors and include benign Brenner tumor, borderline and malignant Brenner tumor, and transitional cell carcinoma. Recent immunohistochemical investigations have reached conflicting



全球贸易项目编号

货号GTIN
345M-150841683137481
345M-170841683137504
345M-140841683137474
345M-160841683137498
345M-180841683137511
345M-16-RUO04061836533052